Preview Newsletter
XARELTO Media Monitoring – Week of 9-17-15
-
Xarelto Lawsuit Update: Internal Bleeding Lawsuit Filed in New York
Sep 16, 2015 | WCIV-TV
By Marc Goldich
BloodThinnerHelp.com reports today on one of the latest Xarelto lawsuit filings. Recently, a Texas woman filed a lawsuit against the manufacturers of Xarelto, Bayer AG and Janssen Pharmaceuticals, the pharmaceutical division of Johnson&Johnson, in the Eastern District of New York. She is alleging that the manufacturer’s failure to adequately warn doctors and patients about the real risks of Xarelto and their failure to perform sufficient safety tests on the drug led to her serious internal bleeding injuries. The full complaint can be found here and is filed under the federal court docket number 1:14-CV-04524. -
Xarelto Lawsuit Update: New Lawsuit Filed Alleges Manufacturers Used Misleading Studies
Sep 15, 2015 | KTRE-TV
By Marc Goldich
BloodThinnerHelp.com reports on a group of recently filed Xarelto lawsuits that allege that Xarelto’s manufacturers, Bayer AG and Janssen Pharmaceuticals, the pharmaceutical division of Johnson&Johnson, not only failed to adequately warn the medical community and patients about the lack of antidote to Xarelto’s anticoagulant effects, but that the heavy advertising campaign and the advertisements the manufacturers placed in medical journals were based on unreliable and poorly managed studies. The case was filed on September 10, 2015 in the U.S. District Court for the Eastern District of Louisiana in theXarelto MDL under case number 2:15-cv-04273. -
Xarelto Lawsuit Update: New Internal Bleeding Lawsuit Filed in Vermont
Sep 17, 2015 | KEYC-TV
By Marc Goldich
BloodThinnerHelp.com reports today on one of the more recently filed Xarelto lawsuits. This lawsuit was filed by the daughter of a deceased man who was prescribed Xarelto to treat his atrial fibrillation and prevent blood clots and stroke. According to the complaint, he was prescribed Xarelto on July 17, 2012 and took the drug regularly until he was hospitalized for a parenchymal hemorrhage. Since he was taking Xarelto at the time, his blood was not able to clot during the hemorrhage which led to an uncontrollable internal bleeding event. After six days in the hospital, he passed away from internal bleeding complications on August 1, 2012. The lawsuit alleges that Xarelto was the cause of the man’s internal bleeding event and death. This case was filed on July 25, 2014 in Vermont federal court under the case number 2:14-CV-00159-CR. -
Location Set For First Xarelto Bellwether Trial, Says Lawsuitsettlementnews.com
Sep 17, 2015 | TheStreet
By MT Services LLC
MT Services LLC, a Lawsuit Settlement News Reporting Company which operates lawsuitsettlementnews.com, announced today that the location has been set for the first Xarelto bellwether trial, which could take place as early as August of 2016. The Xarelto bellwether trials will take place in the Eastern District of Louisiana before U.S. District Judge Eldon Fallon. This information is according to Digital Journal, as well as the fact that as of now, approximately 550 cases have been filed in the federal Xarelto multidistrict litigation (MDL 2592), alleging that Xarelto caused bleeding problems for many individuals. The judge overhearing these cases has recommended that an initial 50 cases be selected for the bellwether trials. The first two bellwether trials will take place in the Eastern District of Louisiana. The third case will be heard in the South District of Texas, and finally, the fourth will take place in the Southern District of Mississippi. -
Xarelto Bleeding Lawsuits See Spike In Filings After Bundling Is Permitted
Sep 14, 2015 | Wright & Schulte LLC
As pretrial proceedings are underway in federal and state courts for Xarelto bleeding lawsuits alleging the anti-clotting drug causes major bleeding events, Wright & Schulte LLC notes that Xarelto filings have increased to more than 1,600 claims. The firm adds that Xarelto lawsuits have risen substantially in the U.S. District Court, Eastern District of Louisiana since Judge Eldon Fallon now allows bundling of Xarelto complaints. Judge Fallon, who is overseeing the coordinated proceedings for the Xarelto complaints, said claims of more than one plaintiff and up to 100 plaintiffs can be filed in a single complaint in order to minimize the expenses of all parties. -
Xarelto Lawsuit Update: Wrongful Death Lawsuit Filed in Xarelto MDL
Sep 14, 2015 | The Legal Herald
By Marc Goldich
BloodThinnerHelp.com reports today on the latest development in Xarelto lawsuit filings. A new federally filed lawsuit was added to the Xarelto multidistrict litigation. The complaint was filed by the son of a man from Georgia who recently passed away due to an internal bleeding event that was allegedly caused by Xarelto usage. -
California Man Files Xarelto Lawsuit Over Bleeding Injury
Sep 14, 2015 | Top Class Actions
By Joanna Szabo
A California resident has recently filed a lawsuit against Janssen Research & Development LLC and Johnson and Johnson Research & Development LLC over personal injuries allegedly caused by Xarelto. Plaintiff Stanley N., was allegedly prescribed Xarelto to treat his atrial fibrillation condition. -
Latest Xarelto Lawsuit Accuses Defendants of Misleading Advertisements
Sep 14, 2015 | LawyersandSettlements.com
By Gordon Gibb
In perhaps one of the most damning commentaries yet on the safety and efficacy of Xarelto, more than two dozen plaintiffs claim in a recently filed Xarelto lawsuit that not only did Xarelto partners Johnson & Johnson (J&J) and Bayer Corp. (Bayer) fail to adequately warn about the lack of an available reversing agent to help stem a Xarelto Bleeding Issue, but that a plethora of advertisements in medical journals relied on studies that were unreliable and poorly managed, or so it has been alleged. Xarelto is one of two latter-day anticoagulants designed as an alternative to the decades-old warfarin (Coumadin). The latter requires constant blood and diet monitoring, but the blood-thinning properties of warfarin can be quickly reversed with the application of vitamin K - a handy weapon in the medical tool belt that can help stem a hemorrhage and give the patient a chance to survive. -
Lawsuits Target Xarelto Bleeding Risks
Sep 17, 2015 | Righting Injustice
By Jennifer Walker-Journey
Bayer’s blood thinner Xarelto is the subject of a growing class action lawsuit alleging bleeding risks in people who used the drug. Xarelto was approved by the Food and Drug Administration in 2011, making it the second in a new class of anticoagulants designed as a more convenient alternative to the long-used warfarin. Xarelto is used to prevent strokes in patients with atrial fibrillation, as well as to prevent or treat blood clots in specific populations of patients. -
Canadian Government Orders Xarelto Investigation
Sep 16, 2015 | The Legal Examiner
By Andy Childers
The number of lawsuits claiming injuries associated with Xarelto continues to grow in the U.S., and regulators in Canada recently announced a safety review into reports of liver injuries connected with Xarelto use. The August 26 Health Canada safety review cites numerous reports of liver injuries among Xarelto users, and the Canadian government will continue to monitor all safety information involving Xarelto.
Plaintiff Attorney Press Releases
Plaintiff Attorney Blog Posts
Plaintiff Attorney Press Releases & Blogs - Canadian Litigation
-
Xarelto Lawsuit Update: Internal Bleeding Lawsuit Filed in New York
Sep 16, 2015 | WCIV-TV
By Marc Goldich
September 16, 2015 – /PressAdvantage/ – BloodThinnerHelp.com reports today on one of the latest Xarelto lawsuit filings. Recently, a Texas woman filed a lawsuit against the manufacturers of Xarelto, Bayer AG and Janssen Pharmaceuticals, the pharmaceutical division of Johnson&Johnson, in the Eastern District of New York. She is alleging that the manufacturer’s failure to adequately warn doctors and patients about the real risks of Xarelto and their failure to perform sufficient safety tests on the drug led to her serious internal bleeding injuries. The full complaint can be found here and is filed under the federal court docket number 1:14-CV-04524.
In this case, the plaintiff was prescribed Xarelto by her doctor and began taking it to prevent blood clots that may be caused by atrial fibrillation, a heart condition. She was using Xarelto for five months when she experienced a severe internal bleeding event that left her seriously injured. The complaint does not specify the injuries sustained but it does note that the injuries she suffered are permanent and will require long term future care.
Xarelto was approved by the Food and Drug Administration, FDA, for released onto the United States market in 2011. Xarelto’s manufacturers pushed the drug as a convenient alternative to the traditional blood thinner Warfarin because of Xarelto’s ‘one size fits all’ dosage and lack of required blood monitoring. Advertisements for the drug were heavily published in medical journals and television commercials for the drug featured well known athletes and public figures. Xarelto was initially approved for usage in patients who suffered from atrial fibrillation, deep vein thrombosis, or who have recently undergone knee or hip replacement surgeries.
The problem with Xarelto is that there is no antidote to the anticoagulant effects of the drug which makes it especially dangerous. If a patient is taking Warfarin and experiences an internal bleeding emergency, a doctor can administer vitamin K to reverse the effects of the Warfarin and the blood will clot. If a patient is taking Xarelto and experiences an internal bleeding emergency, there is no way to stop the bleeding. Xarelto currently has two ‘black box’ warnings attached to it by the FDA. The black box warning is the most strict warning the FDA can assign to a drug short of recalling it.
“If the manufacturers of Xarelto did conceal information about the true dangers of the drug, they deserve to be brought to justice,” Xarelto attorney Marc Goldich said. “If you or a loved one feel that you have been harmed by Xarelto, contact us immediately.”
For any questions regarding this press release or the pending Xarelto litigation, please contact Marc Goldich at (866) 425-8902.
http://www.abcnews4.com/story/30046060/xarelto-lawsuit-update-internal-bleeding-lawsuit-filed-in-new-york
-
Xarelto Lawsuit Update: New Lawsuit Filed Alleges Manufacturers Used Misleading Studies
Sep 15, 2015 | KTRE-TV
By Marc Goldich
BloodThinnerHelp.com reports on a group of recently filed Xarelto lawsuits that allege that Xarelto’s manufacturers, Bayer AG and Janssen Pharmaceuticals, the pharmaceutical division of Johnson&Johnson, not only failed to adequately warn the medical community and patients about the lack of antidote to Xarelto’s anticoagulant effects, but that the heavy advertising campaign and the advertisements the manufacturers placed in medical journals were based on unreliable and poorly managed studies. The case was filed on September 10, 2015 in the U.S. District Court for the Eastern District of Louisiana in theXarelto MDL under case number 2:15-cv-04273.
The plaintiffs claim that the advertisements placed in medical journals focusing on Xarelto’s ability to prevent stroke and pulmonary embolism persuaded doctors to prescribe Xarelto, a much more expensive drug, over safer alternatives such as Warfarin. The plaintiffs also allege that doctors were not made aware of the risks that Xarelto posed because manufacturers did not provide thorough warnings.
Xarelto Lawsuit Alleges Inaccurate Studies Were Used in Marketing:
Plaintiffs in these cases allege that Xarelto’s manufacturers ‘cherry-picked’ the most positive parts of the studies with the intention to try to market the drug in a positive manner and concealed the fact that Xarelto could cause serious internal bleeding injuries and death due to its lack of reversal antidote.
This particular lawsuit details that Xarelto is usually prescribed for non-valvular atrial fibrillation, deep vein thrombosis, and pulmonary embolism and is also prescribed widely for hip and knee replacement patients. Because of the variety of treatments Xarelto was marketed for, the complaint says that it was the most widely advertised drug in medical journals that doctors routinely used to stay updated on the latest pharmaceutical and medical advancements. The lawsuit also alleges that the studies referenced in Xarelto’s marketing materials were unreliable, poorly managed, and filled with false facts, discarded medical records, and instances of improper dosing.
In this group of cases, two of the plaintiffs represent the estates of patients who died of compilations from internal bleeding after taking Xarelto. The plaintiffs in these cases detail the thousands of adverse events that have been linked to Xarelto usage in the United States and the dozens of deaths allegedly linked. The complaint notes that despite these alleged links, neither Johnson&Johnson or Bayer opened any investigative studies or reviews of Xarelto or provided any more warnings to the community.
Xarelto’s Lack of Antidote Can Cause Serious Side Effects:
Xarelto is a new form of anticoagulant that was designed as a more convenient alternative to the traditional blood thinner Warfarin. Warfarin’s effects can be quickly reverse in the event of an internal bleeding emergency by administering Vitamin K but if a patient is taking Xarelto, there is no way to reverse the drugs effects if the patient suffers an internal bleed.
“As Xarelto litigation continues, we expect to see more cases come forward.” Xarelto attorney Marc Goldich said, “If you or a loved one feel that you have been harmed by Xarelto, we strongly encourage you to contact us immediately.”
For any questions regarding this press release or the pending Xarelto litigation, please contact Marc Goldich at (866) 425-8902
http://www.ktre.com/story/30038590/xarelto-lawsuit-update-new-lawsuit-filed-alleges-manufacturers-used-misleading-studies
-
Xarelto Lawsuit Update: New Internal Bleeding Lawsuit Filed in Vermont
Sep 17, 2015 | KEYC-TV
By Marc Goldich
September 17, 2015 – /PressAdvantage/ – BloodThinnerHelp.com reports today on one of the more recently filed Xarelto lawsuits. This lawsuit was filed by the daughter of a deceased man who was prescribed Xarelto to treat his atrial fibrillation and prevent blood clots and stroke. According to the complaint, he was prescribed Xarelto on July 17, 2012 and took the drug regularly until he was hospitalized for a parenchymal hemorrhage. Since he was taking Xarelto at the time, his blood was not able to clot during the hemorrhage which led to an uncontrollable internal bleeding event. After six days in the hospital, he passed away from internal bleeding complications on August 1, 2012. The lawsuit alleges that Xarelto was the cause of the man’s internal bleeding event and death. This case was filed on July 25, 2014 in Vermont federal court under the case number 2:14-CV-00159-CR.
Xarelto Linked to Serious Internal Bleeding:
In this case, the man suffered from a parenchymal hemorrhage, a very severe brain bleed. It is an immediate medical emergency and can be caused by high blood pressure or some kind of trauma. The excessive bleeding in the brain compresses brain tissue and can cut off the brain’s oxygen supply. If a drug such as Xarelto is in the patient’s system, as it was in this case, it completely prevents the blood from clotting. A parenchymal hemorrhage is often difficult to treat and requires extreme life saving measures because detection of the condition usually happens too late. You can find more information about different types of brain bleeds here.
Xarelto Lawsuits Allege The Drug Is Dangerous:
The plaintiff in Vermont is bringing this lawsuit forward as the administrator of the deceased’s estate. She is seeking damages for medical expenses, probate, attorney fees, funeral expenses, pain and suffering, and other expenses related to his estate. The complaint notes that if the plaintiff and her father were aware of the real risks that Xarelto usage posed, they would have chosen one of the safer alternatives available on the market. The complaint alleges that the manufacturers of Xarelto, Bayer AG and Janssen Pharmaceuticals, the pharmaceutical division of Johnson&Johnson, were reckless by releasing the drug onto the market.
Xarelto is a much more dangerous drug than traditional blood thinners, such as Warfarin, because there is no antidote available to reverse its anticoagulant effects. If a patient experiences an internal bleeding event and is taking Warfarin, a doctor will be able to administer vitamin K to the patient and their blood will clot again. If a patient is taking Xarelto and experiences an internal bleed, there is no way to stop the bleeding, which often leads to an uncontrollable internal bleeding event and serious injury.
“As the Xarelto litigation moves forward, we expect to see even more cases filed across the country,” Xarelto attorney Marc Goldich said. “We strongly encourage anyone who feels that they have been harmed by Xarelto usage to contact us immediately.”
For any questions regarding this press release or the pending Xarelto litigation, please contact Marc Goldich at (866) 425-8902.
-
Location Set For First Xarelto Bellwether Trial, Says Lawsuitsettlementnews.com
Sep 17, 2015 | TheStreet
By MT Services LLC
NEW ORLEANS, Sept. 17, 2015 /PRNewswire/ -- MT Services LLC, a Lawsuit Settlement News Reporting Company which operates lawsuitsettlementnews.com, announced today that the location has been set for the first Xarelto bellwether trial, which could take place as early as August of 2016. The Xarelto bellwether trials will take place in the Eastern District of Louisiana before U.S. District Judge Eldon Fallon. This information is according to Digital Journal, as well as the fact that as of now, approximately 550 cases have been filed in the federal Xarelto multidistrict litigation (MDL 2592), alleging that Xarelto caused bleeding problems for many individuals. The judge overhearing these cases has recommended that an initial 50 cases be selected for the bellwether trials. The first two bellwether trials will take place in the Eastern District of Louisiana. The third case will be heard in the South District of Texas, and finally, the fourth will take place in the Southern District of Mississippi.
Lawsuits against Bayer and Johnson & Johnson's subsidiary, Janssen Pharmaceuticals, include claims of serious health problems and even death as a result of uncontrollable bleeding events. There is no known antidote at this time, according to experts. MTS encourages anyone who is looking for lawsuit funding on their Xarelto case, or anyone looking for assistance with finding a Xarelto law firm or lawyer, to contact the company immediately for assistance.
Chris Janish, CEO of MTS, commented on the update in the Xarelto MDL, "We are pleased that a bellwether trial date is less than a year away and that the Xarelto litigation will begin the most important phase of gauging public sentiment as to the drug's danger or safety. Unfortunately, this is really only the start of the litigation and any plaintiffs who were successful would still need to wait a long time to receive any funds from an actual settlement."
MTS is prepared to help those who need lawsuit help with finding a qualified Xarelto law firm or Xarelto lawyer to provide a free evaluation on their specific bleeding case. To learn more about MTS' services involving Xarelto, Pradaxa, or other blood thinner litigations, please visit: http://www.lawsuitsettlementnews.com/pradaxa-all-blood-thinner-cases
If you already have an attorney and have filed a lawsuit and need a lawsuit funding cash advance, not to be confused with a lawsuit loan or pre-settlement loan, Lawsuit Settlement News can help you. Victims of Pradaxa or Xarelto usage and/or complications can apply for up to $50K in pre-settlement or settlement lawsuit funding. For a full list of the services that the company provides, visit:http://www.lawsuitsettlementnews.com/about-our-products-and-services
If you, or a loved one, have been injured by Xarelto or Pradaxa and need lawsuit money or lawsuit help, including finding a Xarelto or Pradaxa law firm, and would like to speak with a live agent who can answer any questions you may have, please call:877.571.0405.
You may also fill out a quick application online at: www.lawsuitsettlementnews.comand an agent will contact you shortly.
http://www.thestreet.com/story/13291703/1/location-set-for-first-xarelto-bellwether-trial-says-lawsuitsettlementnewscom.html
-
Xarelto Bleeding Lawsuits See Spike In Filings After Bundling Is Permitted
Sep 14, 2015 | Wright & Schulte LLC
As pretrial proceedings are underway in federal and state courts for Xarelto bleeding lawsuits alleging the anti-clotting drug causes major bleeding events, Wright & Schulte LLC notes that Xarelto filings have increased to more than 1,600 claims. The firm adds that Xarelto lawsuits have risen substantially in the U.S. District Court, Eastern District of Louisiana since Judge Eldon Fallon now allows bundling of Xarelto complaints. Judge Fallon, who is overseeing the coordinated proceedings for the Xarelto complaints, said claims of more than one plaintiff and up to 100 plaintiffs can be filed in a single complaint in order to minimize the expenses of all parties. Since Judge Fallon issued his order in May, the number of federal Xarelto cases rose from 434 to 1,231 as of August 17. Xarelto bleeding lawsuits are also pending in a multicounty litigation in the Philadelphia Court of Common Pleas in Pennsylvania. The number of Xarelto lawsuits pending slightly increased from 346 as of August 3, to 390 as of September 9. The Xarelto lawsuits pending in the state and federal courts accuses, Xarelto’s maker, Bayer Healthcare Pharmaceuticals, and Johnson & Johnson’s Janssen Pharmaceuticals unit, which markets the blood thinner, of failing to warn that Xarelto does not have an antidote which leaves emergency room doctors without any effective means to treat and stabilize patients who experienced uncontrolled and excessive bleeding. (In re: Xarelto (Rivaroxaban) Products Liability Litigation, MDL 2592) (In Re: Xarelto Litigation, Case Number 150102349)
“The increase in the number of federal Xarelto claims – whether they were filed by one plaintiff or bundled by multiple plaintiffs – clearly shows that patients are still experiencing major bleeding events allegedly due to Xarelto,” says Wright & Schulte LLC, which is representing men and women from across the country in drug lawsuits who believe they have suffered bleeding injuries as a result of taking blood thinners. If you have been injured after using Xarelto contact one of the the firms attorneys at Wright & Schulte LLC by calling 1-800-399-0795 or visit www.yourlegalhelp.com for more information.
Xarelto (rivaroxaban) is an anti-clotting drug approved by the U.S. Food and Drug Administration (FDA) in July 2011 to reduce the risk of blood clots, deep vein thrombosis, and pulmonary embolism following knee or hip replacement surgery. The blood thinner received further approval by the FDA in November 2011 to reduce the risk of stroke in people who have abnormal heart rhythm not caused by a heart valve problem. The federal agency considers Xarelto as a new generation anticoagulant when compared to warfarin (Coumadin, Jantoven), which received FDA approval 60 years ago. Xarelto is more convenient for patients to use because they do not have to monitor their blood on a regular basis like patients who use warfarin. However, Xarelto does not have an antidote to reverse its bleeding effects. Warfarin uses vitamin K as a reversal agent to stop the bleeding.
[fda.gov/Drugs/NewsEvents/ucm405148.htm, July 17, 2014]
[fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm278646.htm, November 4, 2011]The Xarelto complaints filed in state and federal courts purport that Bayer Healthcare and Janssen Pharmaceuticals failed to adequately warn healthcare professionals and their patients about the bleeding risk associated with Xarelto and failed to disclose that the drug does not have an antidote. Court documents indicate that the first two bellwether jury trials for federal Xarelto lawsuits have been scheduled for August 1, 2016, and August 22, 2016, in the Louisiana District Court. The third trial is scheduled on September 12, 2016, in the U.S. District Court, Southern District of Texas, and the fourth trial for October 17, 2016, in the U.S. District Court, Southern District of Mississippi, court records show. (In re: Xarelto (Rivaroxaban) Products Liability Litigation, MDL 2592)
-
Xarelto Lawsuit Update: Wrongful Death Lawsuit Filed in Xarelto MDL
Sep 14, 2015 | The Legal Herald
By Marc Goldich
BloodThinnerHelp.com reports today on the latest development in Xarelto lawsuit filings. A new federally filed lawsuit was added to the Xarelto multidistrict litigation. The complaint was filed by the son of a man from Georgia who recently passed away due to an internal bleeding event that was allegedly caused by Xarelto usage.
This most recent complaint was filed in the Xarelto MDL in Louisiana on March 20, 2015 under case number 2:15-cv-00886. The Xarelto MDL and Philadelphia Mass Tort Group have both been formed to expedite the trial process for all parties involved. The formation of these groups coordinates pretrial discovery and saves time in the litigation of these lawsuits since all of the plaintiffs involved are making similar allegations against defendants Bayer AG and Janssen Pharmaceuticals claiming that their blood thinner Xarelto caused serious injuries and death due to uncontrollable internal bleeding.
Lawsuit Claims Xarelto Side Effects Caused Wrongful Death
The son of the deceased, a Tennessee resident, alleges in the complaint that his father died from an uncontrollable internal bleeding event that is believed to be linked to his Xarelto usage. The complaint details that the deceased was initially prescribed Xarelto to treat atrial fibrillation, a heart condition, in November 2012. Xarelto was approved to treat this condition by the FDA. Unfortunately, in March 2013 the plaintiff’s father passed away due to complications from an internal bleeding event. The complaint states that this would not have happened if the plaintiff and his family knew about the risks that Xarelto presented before his father took the drug. If they knew these risks, they would have looked for a safer alternative.
The complaint alleges that Xarelto’s manufacturers knew that the blood thinner could potentially cause irreversible, serious internal bleeding events and concealed this knowledge from the public. The complaint also outlines how the defendants allegedly did not adequately warn the medical community and patients about Xarelto’s lack of an antidote and also did not advise the medical community on ways to stabilize a patient taking Xarelto in the event that an internal bleeding injury occurred.
Xarelto’s Dangerous Lack of Antidote
According to the National Heart, Lung, and Blood Institute, atrial fibrillation is a very common irregular heart beat that is suffered by more than 3 million people per year in the United States. A recognized treatment for atrial fibrillation in the medical community is with blood thinners. The danger with prescribing Xarelto as opposed to more traditional blood thinners such as Warfarin is that unlike traditional blood thinners, Xarelto does not have an antidote. There is no way to reverse the anticoagulant effects of the drug in an internal bleeding emergency.
“We encourage anybody who feels that they may have been injured by their Xarelto usage to contact us immediately.” Xarelto attorney Marc Goldich said, “We expect to see more Xarelto lawsuits come forward as the litigation proceeds.”
For any questions regarding this press release or the pending Xarelto litigation, please contact Marc Goldich at (866) 425-8902.
http://legalherald.com/xarelto-lawsuit-update-wrongful-death-lawsuit-filed-in-xarelto-mdl/
-
California Man Files Xarelto Lawsuit Over Bleeding Injury
Sep 14, 2015 | Top Class Actions
By Joanna Szabo
A California resident has recently filed a lawsuit against Janssen Research & Development LLC and Johnson and Johnson Research & Development LLC over personal injuries allegedly caused by Xarelto.
Plaintiff Stanley N., was allegedly prescribed Xarelto to treat his atrial fibrillation condition.
After using Xarelto, Stanley underwent a life-threatening adverse event involving excessiveXarelto bleeding, physical pain, and mental anguish.
Stanley filed this Xarelto bleeding lawsuit seeking damages for his hospitalization and medical treatment, as well as other forms of relief.
Multiple different companies were involved in the research, testing, developing, and manufacturing of Xarelto, and are included in the plaintiff’s allegations against the drug.
Xarelto (rivaroxaban), an anticoagulant or prescription blood thinner produced by Bayer Healthcare, is currently facing approximately 1,200 Xarelto lawsuits filed on behalf of patients who after taking Xarelto allegedly experienced gastrointestinal bleeding, hemorrhaging, or other adverse events.
Xarelto is a relatively new drug, introduced in 2011 to replace Coumadin (generic name warfarin) on the market. Xarelto is designed to help at risk individuals for strokes, systemic embolism, deep vein thrombosis (DVT), or pulmonary embolism by reducing potential for blood clotting. Unlike warfarin, Xarelto does not have an antidote available to reverse or reduce its sometimes dangerous effects.
Xarelto was approved by the U.S. Food and Drug Administration in 2011 for the preventive treatment of DVT and PE, and later that year also received FDA approval to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation.
Studies conducted in clinical trials prior to the 2011 FDA approval of Xarelto, known as the “RECORD” studies, showed that rivaroxaban was superior to its competitor enoxaparin for preventing disease after total knee and hip arthroplasty. However, the RECORD studies also showed a greater risk of bleeding with Xarelto.
Another study showed that Xarelto was associated with a higher risk of bleeding from gastrointestinal sites than was its competitor.
The Xarelto bleeding lawsuit alleges that the defendants used the results of these and similar studies to add to their marketing campaign materials, and considered them as completely positive results. However, these promotional materials failed to show the studies’ findings of increased risk of the Xarelto bleeding concerns through these studies.
Xarelto has quickly become one of the top selling medications in the United States. By the end of 2013, approximately 1 million Xarelto prescriptions had been written in the U.S., though the drug was only approved for the market in 2011.
One of Xarelto’s marketed advantages in the lack of necessity for regular blood monitoring, which is required for users of warfarin, a competitor. Allegations from this Xarelto lawsuit and other like it indicate that Xarelto would be safer if combined with regular blood monitoring.
In this Xarelto bleeding lawsuit, the plaintiff claims that the drug manufacturers did not adequately warn about the drug’s potentially damaging side effects on their packaging, in their advertising, or to the medical community as a whole.
Robinson filed this Xarelto bleeding lawsuit on multiple counts, including strict liability, breach of implied warranty, failure to warn, negligence, fraud, and more.
If you or someone you know has experienced Xarelto side effects such as Xarelto bleeding, you may be able to join a class action lawsuit.
The Xarelto Bleeding Lawsuit is Case No. 2:15-cv-03713-EEF-MBN, in the U.S. District Court for the Eastern District of Louisiana.
http://topclassactions.com/lawsuit-settlements/lawsuit-news/145407-california-man-files-xarelto-lawsuit-over-bleeding-injury/
-
Latest Xarelto Lawsuit Accuses Defendants of Misleading Advertisements
Sep 14, 2015 | LawyersandSettlements.com
By Gordon Gibb
In perhaps one of the most damning commentaries yet on the safety and efficacy of Xarelto, more than two dozen plaintiffs claim in a recently filed Xarelto lawsuit that not only did Xarelto partners Johnson & Johnson (J&J) and Bayer Corp. (Bayer) fail to adequately warn about the lack of an available reversing agent to help stem a Xarelto Bleeding Issue, but that a plethora of advertisements in medical journals relied on studies that were unreliable and poorly managed, or so it has been alleged.
Xarelto is one of two latter-day anticoagulants designed as an alternative to the decades-old warfarin (Coumadin). The latter requires constant blood and diet monitoring, but the blood-thinning properties of warfarin can be quickly reversed with the application of vitamin K - a handy weapon in the medical tool belt that can help stem a hemorrhage and give the patient a chance to survive.
Xarelto was introduced to the market a few years ago amidst claims that such stringent monitoring was not needed, allowing for less ongoing medical intervention and heightened convenience. Unlike warfarin, however, there was no means of reversing the blood-thinning properties of Xarelto in the event of a serious Xarelto Bleedout.
“The use of Xarelto without appropriate blood monitoring, dose adjustment and twice a day dosing can cause major, life-threatening bleeding events,” the plaintiffs said. “Importantly, Xarelto’s significant risk of severe, and sometimes fatal, internal bleeding has no antidote to reverse its effects.”
The lawsuit notes that Xarelto is primarily prescribed for nonvalvular atrial fibrillation, deep vein thrombosis or pulmonary embolism - but is also employed in the treatment protocols of patients in receipt of hip and knee replacements. Thus, Xarelto cuts a wide swath and at one point, according to the Xarelto Bleeding Complications lawsuit, it was the most widely advertised drug in medical journals routinely used by doctors to keep abreast of the latest medical and pharmaceutical advancements.
However, plaintiffs accuse J&J and Bayer of cherry-picking the more positive aspects of studies for marketing purposes, while concealing the possibility of Xarelto death through a bleeding issue that could not be controlled by way of a reversing agent.
Two of the plaintiffs in the latest Xarelto lawsuit represent the estates of patients who died of severe bleeding. Plaintiffs note the existence of thousands of “adverse events” linked to the use of Xarelto in both the US and Germany, not to mention reports of dozens of deaths in both countries. Even then, according to the complaint, neither J&J nor Bayer undertook any additional investigative studies into Xarelto, or provide additional and more adequate warnings.
When the US Food and Drug Administration (FDA) approved Xarelto (Rivaroxaban), the agency did so based on data it viewed as sufficient to regard Xarelto as having an appropriate risk/benefit profile for the intended community of patients.
The Xarelto lawsuit claims that studies referenced in marketing materials to doctors were not only unreliable and poorly managed, but were also encumbered by instances of falsification, discarded medical records and improper dosing, or so it is alleged.Advertisements in medical journals focused on Xarelto’s capacity to prevent stroke and systemic embolism and induced doctors to prescribe the more expensive and convenient Xarelto over safer alternatives such as warfarin. Plaintiffs claim that physicians were not aware of risks inherent to Xarelto, and claim the manufacturers failed to provide adequate earnings.
“Defendants’ fraudulent representations and concealment evidence flagrant, willful, and depraved indifference to health, safety, and welfare,” the plaintiffs said, accusing the companies of acting with “callous indifference.”
Xarelto lawsuits alleging Xarelto Bleeding complications and Xarelto death have been consolidated in multidistrict litigation in Louisiana. This latest lawsuit was filed September 10 in the Eastern District of Louisiana.
The case is Adams et al v. Janssen Research & Development LLC f/k/a Johnson and Johnson Pharmaceutical Research and Development LLC et al, Case No. 2:15-cv-04273 in the US District Court for the Eastern District of Louisiana.http://www.lawyersandsettlements.com/articles/xarelto/xarelto-lawsuit-death-bleeding-issue-25-20910.html#.VfoDeRHBzRY
-
Lawsuits Target Xarelto Bleeding Risks
Sep 17, 2015 | Righting Injustice
By Jennifer Walker-Journey
Bayer’s blood thinner Xarelto is the subject of a growing class action lawsuit alleging bleeding risks in people who used the drug.
Xarelto was approved by the Food and Drug Administration in 2011, making it the second in a new class of anticoagulants designed as a more convenient alternative to the long-used warfarin. Xarelto is used to prevent strokes in patients with atrial fibrillation, as well as to prevent or treat blood clots in specific populations of patients.
Xarelto and other drugs in its class are considered more convenient than warfarin because patients taking them do not have to be regularly monitored as patients taking warfarin do.
However, like warfarin, Xarelto and other blood thinners are associated with an increased risk of bleeding events. These events can range from rectal bleeding and eye bleeds to bleeding in the gastrointestinal tract and brain hemorrhages. Deaths have also been associated with the drugs.
Unlike warfarin, there is no antidote to reverse the blood thinning effects of Xarelto. Thus bleeding can go uncontrolled and become life threatening.
The lawsuits alleging bleeding risks with Xarelto claim Bayer did not adequately warn the public ofXarelto side effects, and that the drug caused both physical and emotional injuries to patients as well as their loved ones.
Attorneys with Beasley Allen Law Firm are currently investigating bleeding injuries in patients who took the blood thinner Xarelto.
http://www.rightinginjustice.com/news/2015/09/14/lawsuits-target-xarelto-bleeding-risks/
-
Canadian Government Orders Xarelto Investigation
Sep 16, 2015 | The Legal Examiner
By Andy Childers
The number of lawsuits claiming injuries associated with Xarelto continues to grow in the U.S., and regulators in Canada recently announced a safety review into reports of liver injuries connected with Xarelto use.
The August 26 Health Canada safety review cites numerous reports of liver injuries among Canadian Xarelto users, and the Canadian government will continue to monitor all safety information involving Xarelto.
What is Xarelto Used For?
Xarelto (rivaroxaban) is used to prevent blood clots from forming in patients who have undergone hip or knee replacement surgery, and also to treat or prevent blood clots from forming in a deep vein, typically in the leg, known as deep vein thrombosis, or in a blood vessel that supplies the lungs (pulmonary embolism), and to reduce the risk of stroke in patients with irregular heartbeat. Xarelto was first sold in Canada in September 2008.
Safety Review
At the time of the safety review, there were 61 Canadian reports of liver-related adverse effects in patients taking the blood thinner Xarelto. A review of international data from the World Health Organization’s database showed 431 cases of liver injury, and Xarelto was confirmed to be the only drug used in 23 of these cases; therefore, a clear link between Xarelto and liver injury could not be established.
Despite the findings, Health Canada has said it will continue to monitor safety information involving Xarelto, identify and assess any potential harm, and take appropriate and timely action should any new health risks be identified.
Xarelto Lawsuits Pending in the U.S.
In August 2015, the Philadelphia Court of Common Pleas combined several lawsuits alleging dangerous side effects associated with Xarelto use, and almost 400 separate cases were consolidated in mass tort litigation in Philadelphia. As of August 30, 2015, approximately 1,231 lawsuits have been consolidated for pretrial proceedings in a multidistrict litigation (MDL) in the eastern district of Louisiana.
http://atlanta.legalexaminer.com/defective-dangerous-products/canadian-government-orders-xarelto-investigation/
Plaintiff Attorney Press Releases
Plaintiff Attorney Blog Posts
Plaintiff Attorney Press Releases & Blogs - Canadian Litigation
Add recipients
Suggested